⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7099500 | 0.86 | — | — | |
| SCHEMBL8532732 | 0.82 | — | — | |
| SCHEMBL9423991 | 0.82 | — | — | |
| SCHEMBL7622829 | 0.81 | — | — | |
| SCHEMBL7054490 | 0.80 | — | — | |
| SCHEMBL7622834 | 0.80 | — | — | |
| SCHEMBL8954129 | 0.79 | — | — | |
| SCHEMBL8954087 | 0.79 | — | — | |
| SCHEMBL9210011 | 0.78 | — | — | |
| SCHEMBL9210018 | 0.78 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 47 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20030166700-A1 | Administering a substituted imidazoles to a mammal for the treatment of athroma progression and regression | SMITHKLINE BEECHAM P.L.C. | 2003-09-04 | — | — | US | disclosed |
| US-20030096851-A1 | Medicament | SMITHKLINE BEECHAM P.L.C. | 2003-05-22 | — | — | US | disclosed |
| US-20030069293-A1 | Medicament | SMITHKLINE BEECHAM PLC | 2003-04-10 | — | — | US | disclosed |
| US-20030050285-A1 | Substituted imidazoles; angiotensin II receptor antagonist for the treatment of hemorrhagic stroke | SMITHKLINE BEECHAM P.L.C. | 2003-03-13 | — | — | US | disclosed |
| US-20030004201-A1 | Medicament | SMITHKLINE BEECHAM P.L.C. | 2003-01-02 | — | — | US | disclosed |
| US-20020160985-A1 | Medicament | SMITHKLINE BEECHAM PLC | 2002-10-31 | — | — | US | disclosed |
| US-20020086893-A1 | Imidazole based angiotensin II receptor antagonist for treating haemorrhagic stroke | SMITHKLINE BEECHAM P.L.C. | 2002-07-04 | — | — | US | disclosed |
| US-20020068759-A1 | Medicament | SMITHKLINE BEECHAM PLC | 2002-06-06 | — | — | US | disclosed |
| US-20020058686-A1 | Medicament | SMITHKLINE BEECHAM P.L.C. | 2002-05-16 | — | — | US | disclosed |
| US-20020006949-A1 | Medicament | SMITHKLINE BEECHAM P.L.C. | 2002-01-17 | — | — | US | disclosed |
| WO-1992010097-A1 | ANGIOTENSIN II RECEPTOR BLOCKING COMPOSITIONS | SMITHKLINE BEECHAM CORPORATION (US) | 1992-06-25 | — | — | WO | disclosed |
| WO-1992010186-A1 | USE OF ANGIOTENSN II RECEPTOR ANTAGONISTS FOR THE PREPARATION OF A MEDICAMENT FOR IMPROVING COGNITIVE FUNCTION | SMITHKLINE BEECHAM PLC (GB) | 1992-06-25 | — | — | WO | disclosed |
| WO-1992010183-A1 | USE OF ANGIOTENSIN II RECEPTOR ANTAGONISTS IN THE TREATMENT OF DIABETIC RETINOPATHY | SMITHKLINE BEECHAM PLC (GB) | 1992-06-25 | — | — | WO | disclosed |
| WO-1992010185-A1 | USE OF ANGIOTENSIN II RECEPTOR ANTAGONISTS IN THE PREVENTION OF RESTINOSIS | SMITHKLINE BEECHAM PLC (GB) | 1992-06-25 | — | — | WO | disclosed |
| WO-1992010184-A1 | USE OF ANGIOTENSIN II RECEPTOR ANTAGONISTS IN THE TREATMENT OF ATHEROMA | SMITHKLINE BEECHAM PLC (GB) | 1992-06-25 | — | — | WO | disclosed |
| WO-1992010188-A1 | USE OF ANGIOTENSIN II RECEPTOR ANTAGONISTS IN THE TREATMENT OF HEMORRAGIC STROKE | SMITHKLINE BEECHAM PLC (GB) | 1992-06-25 | — | — | WO | disclosed |
| WO-1992010180-A1 | USE OF ANGIOTENSIN II ANTAGONIST IN THE TREATMENT OF INFARCTION | SMITHKLINE BEECHAM PLC (GB) | 1992-06-25 | — | — | WO | disclosed |
| WO-1992010182-A1 | USE OF ANGIOTENSIN II RECEPTOR ANTAGONISTS IN THE TREATMENT OF DIABETIC NEPHROPATHY | SMITHKLINE BEECHAM PLC (GB) | 1992-06-25 | — | — | WO | disclosed |
| WO-1992010187-A1 | USE OF ANGIOTENSIN II ANTAGONISTS IN THE TREATMENT OF ANGINA PECTORIS | SMITHKLINE BEECHAM PLC (GB) | 1992-06-25 | — | — | WO | disclosed |
| WO-1992002510-A1 | SUBSTITUTED [1H-IMIDAZOL-5-YL]ALKANOIC ACIDS | SMITHKLINE BEECHAM CORPORATION (US) | 1992-02-20 | — | — | WO | disclosed |